Botanix Pharmaceuticals Ltd has released a press release.
BTX 1204 Atopic Dermatitis Study Results Presentation
Filed with ASX ·
Watch Botanix Pharmaceuticals' latest callBotanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call · Replay · Mar 2Read the transcript of Botanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Botanix Pharmaceuticals Limited on 6ix
In the deck
Story so far
Earlier from Botanix Pharmaceuticals
- Botanix Announces Successful Atopic Dermatitis Study Results
- Presentation on Atopic Dermatitis Market
- FDA Green Light for BTX 1503 Phase 2 Study
- Appendix 4C - quarterly
- Enrolment of BTX 1204 Atopic Dermatitis Study Completed
Later from Botanix Pharmaceuticals
- Australian Ethics approval for Acne Study
- Botanix Raises A$8m in Oversubscribed Placement
- BOT Welcomes First FDA Approval for Cannabidiol Product
- First Patients Recruited into BTX 1503 Phase 2 Acne Trial
- Botanix update on development pipeline products
Follow Botanix Pharmaceuticals into a list and get an email when it puts out news.
Follow Botanix Pharmaceuticals